Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030


The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

Regional Insights

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region’s investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Patient-Derived Xenograft/PDX Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Growing demand for personalized medicine
Oncology and preclinical development
Government programs funding and services for applicants in the preparation of their preclinical programs and documentation

Market Restraints

High cost of personalized PDX model

Market Opportunities

Rising demand for humanized PDX Model
Growth in pharma R&D

Market Challenges

Stringent guidelines regarding the ethical use of animals in cancer research

Market Segmentation Analysis

Type: Extensive use of mouse models in oncology to develop novel therapeutics
Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
End-User: Rising applicability of patient-derived xenografts in academic and research institutes

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Patient-Derived Xenograft/PDX Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec’s 3D Spheroid Screening Platform, Kiya-Predict

Kiyatec and XenoSTART partnered to accelerate biopharmaceutical drug development through collaboration. Kiyatec's ex vivo 3D spheroid screening platform, combined with XenoSTART's Patient-Derived Xenograft (XPDX) models, aims to expedite the evaluation of therapeutic efficacy and in vivo outcomes using primary human tumors and tissues from XenoSTART's XPDX library.

Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts

The Soteria Precision Medicine Foundation and Certis Oncology Solutions have joined forces to conduct a clinical study utilizing the CertisAI platform. This study aims to predict the response of patients with KRAS-mutated cancers to different drugs. To test the therapies, orthotopic patient-derived xenografts will be utilized, and the response will be monitored using a mouse-sized MRI instrument.

GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio

GemPharmatech Co., Ltd. reached a strategic license agreement with Charles River Laboratories, Inc. This exclusive agreement grants GemPharmatech the distribution rights for their next generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The NCG mouse lines are an extensive portfolio of immunodeficient research models, specifically designed for cancer immunotherapy research utilizing Patient Derived Xenograft (PDX) models.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Patient-Derived Xenograft/PDX Model Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Mice Models
Rat Models
Tumor Type
Gastrointestinal Tumor Models
Gynecological Tumor Models
Hematological Tumor Models
Respiratory Tumor Models
Urological Tumor Models
Application
Basic Cancer Research
Biomarker Analysis
Preclinical Drug Development
End-User
Academic & Research Institutions
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for personalized medicine
5.1.1.2. Oncology and preclinical development
5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
5.1.2. Restraints
5.1.2.1. High cost of personalized PDX model
5.1.3. Opportunities
5.1.3.1. Rising demand for humanized PDX Model
5.1.3.2. Growth in pharma R&D
5.1.4. Challenges
5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
5.2. Market Segmentation Analysis
5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Patient-Derived Xenograft/PDX Model Market, by Type
6.1. Introduction
6.2. Mice Models
6.3. Rat Models
7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type
7.1. Introduction
7.2. Gastrointestinal Tumor Models
7.3. Gynecological Tumor Models
7.4. Hematological Tumor Models
7.5. Respiratory Tumor Models
7.6. Urological Tumor Models
8. Patient-Derived Xenograft/PDX Model Market, by Application
8.1. Introduction
8.2. Basic Cancer Research
8.3. Biomarker Analysis
8.4. Preclinical Drug Development
9. Patient-Derived Xenograft/PDX Model Market, by End-User
9.1. Introduction
9.2. Academic & Research Institutions
9.3. Contract Research Organizations
9.4. Pharmaceutical & Biotechnology Companies
10. Americas Patient-Derived Xenograft/PDX Model Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec’s 3D Spheroid Screening Platform, Kiya-Predict
13.3.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
13.3.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings